Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Less Invasive Techniques Transform Surgical Management of Breast Cancer

December 17th 2018

Judy C. Boughey, MD, discusses the surgical management of the axilla in patients with node-positive breast cancer and less invasive approaches for disease management.

Expert Addresses Controversies in Management of HR+ Early-Stage Breast Cancer

December 16th 2018

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC

December 14th 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).

Dr. O'Regan on Future of Chemotherapy in Breast Cancer

December 11th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

CDK4/6 Inhibitors Are Transforming Treatment in HR+ Breast Cancer

December 11th 2018

Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.

TAILORx Analysis Underscores Racial Disparity in Breast Cancer Outcomes

December 11th 2018

African-American patients with early breast cancer had worse outcomes than Caucasian patients following adjuvant therapy, despite having a similar risk of recurrence and receiving similar types of therapy, according to subgroup analysis of the phase III TAILORx trial.

TAILORx Update Shows Different PRO Profiles for Chemo, Endocrine Therapy for Breast Cancer

December 10th 2018

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

CAR T-Cell Therapy Shows Early Potential in TNBC

December 8th 2018

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes

December 8th 2018

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.

Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer

December 8th 2018

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients

December 8th 2018

Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.

Exercise Helps Women Maintain Cardiovascular Function During Adjuvant Breast Cancer Treatment

December 7th 2018

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

Palbociclib Combo Active in HER2+ Breast Cancer

December 7th 2018

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors

December 7th 2018

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer

December 7th 2018

Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.

Dr. Spring on the Association Between pCR and Neoadjuvant Chemotherapy

December 7th 2018

Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Dr. Leon Ferre on the Results of the Randomized Trial of Oxybutynin for Hot Flashes

December 7th 2018

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Extended PFS Observed in Alpelisib Combo for PIK3CA-Mutant Breast Cancer

December 7th 2018

Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.

HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer

December 7th 2018

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.

Axillary Radiotherapy Alternative to Lymph Node Dissection in Early-Stage Breast Cancer

December 7th 2018

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.